For this reason, we decided to explore the possible protective role of empagliflozin (EMPA) in curbing the progression of liver fibrosis in thioacetamide (TAA)-intoxicated rats via targeting AMP-activated protein kinase (AMPK)/Sirtuin-1 (SIRT-1) activity and via inhibiting Hypoxia-inducible factor 1-alpha (HIF-1α). Here, HIF1A is linked to Hepatic fibrosis.